Seller record · Telehealth service

Direct Meds

Fails 3 of 8 criteria. S3, pharmacy identification: Prepared by licensed compounding pharmacies, which may vary; none is named. 2 more criteria also fail; see the table below.

At a glance

Direct MedsTelehealth service

5/8criteria passed
Price
Semaglutide from $249, tirzepatide $399 a month
Sells
compounded semaglutide (sublingual and injection), tirzepatide, NAD+, and 3 more
FDA letters
1 on file

Partner link. The site earns a commission on care started through it. Funding

Visit Direct MedsSee all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide. An FDA warning letter names the operating entity, and the seller continues to operate.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSDirect Meds' how it works page
S2Prescription gatingPASSDirect Meds' semaglutide product page
S3Pharmacy identificationFAILDirect Meds' terms
S4Compounding disclosureFAILDirect Meds' tirzepatide product page; Direct Meds' website
S5Analytical documentationFAILDirect Meds' how it works page
S6Business addressPASSDirect Meds' website
S7Price disclosurePASSDirect Meds' how it works page
S8Enforcement statusPASSFDA's website; FDA warning letter 716822

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date. A row that was re-checked later states its own date.

S1PASSThe site states care begins with an evaluation from a licensed provider.Source: Direct Meds' how it works page.
S2PASSA medical intake precedes any shipment; medication ships only if prescribed.Source: Direct Meds' semaglutide product page.
S3FAILPrepared by licensed compounding pharmacies, which may vary; none is named.Source: Direct Meds' terms.
S4FAILThe tirzepatide product page lists “FDA approved for long term weight loss” among the features of the tirzepatide it sells, and the site describes the drugs it offers as compounded. The footer states that compounded medications are not FDA-approved, which does not withdraw the claim on the product page.Source: Direct Meds' tirzepatide product page; Direct Meds' website · read September 2026.
S5FAILThe how-it-works and semaglutide pages state that medications undergo third-party testing for purity, safety and potency, and no certificate, lot number or laboratory is named or reachable.Source: Direct Meds' how it works page · read September 2026.
S6PASSA stated Houston, Texas address; a private mailbox, recorded as such.Source: Direct Meds' website.
S7PASSPrices printed on public pages: semaglutide from $249, tirzepatide $399 monthly.Source: Direct Meds' how it works page.
S8PASSFDA warning letter 716822, September 2025, names the operating company of Direct Meds over its online sale and labeling of compounded semaglutide and tirzepatide. No close-out letter appears in the index. No FDA action has halted the business, and the seller continues to operate.Source: FDA's website; FDA warning letter 716822.

Products shown on the seller's own pages at the recorded date: compounded semaglutide (sublingual and injection), tirzepatide, NAD+, sermorelin, glutathione, BPC-157.

Enforcement documents on file: 1 warning letter

FDA warning letter 716822, issued September 2025, to the operating company of Direct Meds dba DirectMedsClaims on Direct Meds' website that compounded semaglutide and tirzepatide use the same active ingredients as the brand drugs imply equivalence to an approved product and are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Partner link. The site earns a commission on care started through it. Funding.

Visit Direct Meds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.